Themis Medicare Limited has announced the allotment of 60,000 equity shares under its Employee Stock Option Scheme 2012 (ESOP 2012) on December 11, 2025. The pharmaceutical company's Allotment Committee of the Board of Directors approved this issuance during their meeting held on the same date.

ESOP Allotment Details

The allotment involves equity shares with specific parameters that demonstrate the company's commitment to employee participation in ownership:

The shares were issued to eligible employees upon exercise of options that had vested under the company's established employee stock option framework.

Impact on Share Capital

The allotment has resulted in a measurable increase in the company's equity base:

This represents a modest expansion of the company's share capital structure, reflecting the ongoing implementation of its employee incentive programs.

Regulatory Compliance and Share Characteristics

Themis Medicare has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company filed the required statements with both BSE Limited and National Stock Exchange of India Limited, where its shares are listed under scrip code 530199 and symbol THEMISMED respectively.

The newly allotted equity shares maintain identical characteristics to existing shares. All shares issued under the stock option exercise rank pari-passu with the company's existing equity shares, ensuring uniform rights and privileges for all shareholders.

Company Background

Themis Medicare Limited operates in the pharmaceutical sector with its registered office located at Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi, Gujarat. The company's corporate identification number is L24110GJ1969PLC001590, and it maintains its corporate office in Mumbai. The ESOP scheme under which these shares were allotted was established in 2012 and received in-principle approvals from stock exchanges in January 2013.

Themis Medicare Limited , a prominent player in the pharmaceutical sector, has reported a financial setback in its Q2 results for the fiscal year 2026. The company faced significant challenges that led to a substantial downturn in its financial performance compared to the same period last year.

Financial Highlights

All figures in Rs. lakhs

Key Developments

Merger Withdrawal

The company's Board withdrew the proposed merger scheme with Gujarat Themis Biosyn Limited, which was originally approved in November 2024. Gujarat Themis Biosyn decided to focus on its core fermentation-based pharmaceutical business and withdrew from the merger in June 2025.

UK Subsidiary

Themis Medicare received approval for striking off its UK subsidiary Carpo Medicals Limited, resulting in exceptional items of Rs 129.39 lakhs.

Business Focus

Themis Medicare will continue focusing on its domestic pharmaceutical formulations business. The company operates solely in the pharmaceuticals segment.

Future Outlook

While specific guidance for future quarters was not provided, the withdrawal of the planned merger with Gujarat Themis Biosyn Limited suggests a strategic refocus. The company's decision to concentrate on its core domestic formulations business indicates its commitment to achieving long-term sustainable growth.

Investors and stakeholders will be closely monitoring Themis Medicare's performance in the coming quarters for signs of recovery and the effectiveness of its renewed focus on core operations.

Themis Medicare Limited will need to address the challenges that led to this quarter's performance and implement strategies to return to profitability in the coming periods.